Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Reversible nanoencapsulation technology may make it possible to deliver high molecular weight drugs directly to target cancer cells, increasing efficacy and reducing side effects.

UCLA Researchers Develop Nanocapsule for Targeted Delivery of Large-Molecule APIs

Jennifer Markarian is manufacturing reporter for Pharmaceutical Technology.

Experts, including researchers at I Holland, Natoli, and Rutgers Universityâ€™s Engineering Research Center for Structured Organic Particulate Systems, are seeking a greater understanding of the fundamental causes of tablet sticking and are developing predictive models to more quickly find solutions to specific sticking problems.

Researchers Seek Solutions to Tablet Sticking

RABS is a flexible barrier system that maximizes product control but minimizes operator interaction when best practices are followed.

Best Practices for Restricted Access Barrier Systems in Aseptic Manufacturing

Rapid screening of critical API properties can quickly identify the best approach for increasing bioavailability.

Parallel Screening of Solid-State Characteristics Aids Formulation of Poorly Soluble Drugs

Melanie Sena is community editor of Pharmaceutical Technology.

The companies initially focused on five biosimilar products.

Oncobiologics and InVentive Health Clinical Form Biosimilars Pact

Adamis Pharmaceuticals agrees to license and potentially acquire 3M's Taper Dry Powder Inhaler technology.

Adamis Pharmaceuticals Licenses 3M's Dry Powder Inhaler Technology

Patricia Van Arnum was executive editor of Pharmaceutical Technology.

Pfizer, Merck, Sanofi, and AstraZeneca are among the companies reporting revenue declines from generic-drug incursion. A look at what the companies are doing to stimulate growth.

Pfizer, Merck, Sanofi, and AstraZeneca Facing the Generic-Drug Squeeze

A new study reveals how a promising anticancer specifically kills prostate cancer cells by compromising their ability to withstand environmental stress.

Researchers Uncover How a Potent Compound Kills Prostate Cancer Cells

Extensive comparability testing is required to ensure that biosimilars have comparable profiles to their reference products.

Demonstrating Biosimilarity

Antoinette Konski is a partner at Foley & Lardner, akonski@foley.com

The US Supreme Court's Myriad decision satisfied both patient groups and patent holders